Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
13°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ideaya Biosciences Inc
(NQ:
IDYA
)
26.60
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ideaya Biosciences Inc
< Previous
1
2
3
4
Next >
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
November 15, 2024
Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38.
Via
Benzinga
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
November 05, 2024
Via
Benzinga
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate
September 23, 2024
IDEAYA Biosciences released interim Phase 2 data that shows promising tumor shrinkage and eye preservation rates.
Via
Benzinga
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday
September 10, 2024
Via
Benzinga
IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024
August 06, 2024
IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Unveiling 5 Analyst Insights On IDEAYA Biosciences
May 08, 2024
Via
Benzinga
Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews
March 08, 2024
Via
Benzinga
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 6 Experts
February 21, 2024
Via
Benzinga
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal
August 03, 2024
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,...
Via
Talk Markets
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 10, 2024
Via
Benzinga
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
July 10, 2024
Via
Benzinga
Recap: IDEAYA Biosciences Q4 Earnings
February 20, 2024
Via
Benzinga
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 8 Experts
January 26, 2024
Via
Benzinga
Critical Insights From IDEAYA Biosciences Analyst Ratings: What You Need To Know
January 10, 2024
Via
Benzinga
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 08, 2024
Via
Benzinga
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
July 08, 2024
IDEAYA Biosciences reports promising Phase 2 clinical data for IDE397 in MTAP-deletion urothelial and NSCLC patients. The study shows a 39% overall response rate, 94% disease control rate, and a...
Via
Benzinga
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
July 08, 2024
Via
Benzinga
8 Analysts Have This to Say About IDEAYA Biosciences
November 30, 2023
Via
Benzinga
The Latest Analyst Ratings for IDEAYA Biosciences
November 13, 2023
Via
Benzinga
Why Ideaya Biosciences Just Made Its Most Bullish Move Since March
July 08, 2024
The company is working on a treatment for cancers tied to a genetic alteration called MTAP deletion.
Via
Investor's Business Daily
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
July 08, 2024
Via
Benzinga
IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024
May 07, 2024
IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Goldman Sachs Maintains Buy Rating for IDEAYA Biosciences: Here's What You Need To Know
January 25, 2024
Via
Benzinga
Chart Of The Day: IDEAYA Biosciences - Oncology Biomedicine
January 11, 2024
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using...
Via
Talk Markets
Why Ideaya Biosciences Stock Is Plummeting Today
October 25, 2023
Ideaya stock is getting hit hard following a recent press release from the company.
Via
The Motley Fool
Where IDEAYA Biosciences Stands With Analysts
October 11, 2023
Via
Benzinga
7 Analysts Have This to Say About IDEAYA Biosciences
September 12, 2023
Via
Benzinga
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
October 25, 2023
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ.
Via
Benzinga
Why IDEAYA Biosciences Stock Is Falling During Wednesday's Session
October 25, 2023
Ideaya Biosciences Inc (NASDAQ: IDYA) shares are trading lower by 11.6% to $24.10 Wednesday morning after the company priced an underwritten public offering of common stock and pre-funded warrants.
Via
Benzinga
Alphabet, Texas Instruments, CoStar Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 25, 2023
U.S. stock futures traded mixed this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.